Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 13 November 1992:
Vol. 258. no. 5085, pp. 1148 - 1152
DOI: 10.1126/science.1439824
Prev | Table of Contents | Next

Articles

Science, Vol 258, Issue 5085, 1148-1152
Copyright © 1992 by American Association for the Advancement of Science

articles

Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22

LA Cannon-Albright, DE Goldgar, LJ Meyer, CM Lewis, DE Anderson, JW Fountain, ME Hegi, RW Wiseman, EM Petty, AE Bale, and al. et

Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City 84132.

Linkage analysis of ten Utah kindreds and one Texas kindred with multiple cases of cutaneous malignant melanoma (CMM) provided evidence that a locus for familial melanoma susceptibility is in the chromosomal region 9p13-p22. The genetic markers analyzed reside in a candidate region on chromosome 9p21, previously implicated by the presence of homozygous deletions in melanoma tumors and by the presence of a germline deletion in an individual with eight independent melanomas. Multipoint linkage analysis was performed between the familial melanoma susceptibility locus (MLM) and two short tandem repeat markers, D9S126 and the interferon-alpha (IFNA) gene, which reside in the region of somatic loss in melanoma tumors. An analysis incorporating a partially penetrant dominant melanoma susceptibility locus places MLM near IFNA and D9S126 with a maximum location score of 12.71. Therefore, the region frequently deleted in melanoma tumors on 9p21 presumably contains a locus that plays a critical role in predisposition to familial melanoma.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Evidence for an Inherited Predisposition Contributing to the Risk for Rotator Cuff Disease.
R. Z. Tashjian, J. M. Farnham, F. S. Albright, C. C. Teerlink, and L. A. Cannon-Albright (2009)
J. Bone Joint Surg. Am. 91, 1136-1142
   Abstract »    Full Text »    PDF »
CDKN2A/p16 Genetic Test Reporting Improves Early Detection Intentions and Practices in High-Risk Melanoma Families.
L. G. Aspinwall, S. L. Leaf, E. R. Dola, W. Kohlmann, and S. A. Leachman (2008)
Cancer Epidemiol. Biomarkers Prev. 17, 1510-1519
   Abstract »    Full Text »    PDF »
Epigenetic Regulation Identifies RASEF as a Tumor-Suppressor Gene in Uveal Melanoma.
W. Maat, S. H. W. Beiboer, M. J. Jager, G. P. M. Luyten, N. A. Gruis, and P. A. van der Velden (2008)
Invest. Ophthalmol. Vis. Sci. 49, 1291-1298
   Abstract »    Full Text »    PDF »
Aggregation of Cancer in First-Degree Relatives of Patients with Glioma.
M. E. Scheurer, C. J. Etzel, M. Liu, R. El-Zein, G. E. Airewele, B. Malmer, K. D. Aldape, J. S. Weinberg, W.K. A. Yung, and M. L. Bondy (2007)
Cancer Epidemiol. Biomarkers Prev. 16, 2491-2495
   Abstract »    Full Text »    PDF »
Modeling Inheritance of Malignant Melanoma With DNA Markers in Sinclair Swine.
L. Gomez-Raya, M. Okomo-Adhiambo, C. Beattie, K. Osborne, A. Rink, and W. M. Rauw (2007)
Genetics 176, 585-597
   Abstract »    Full Text »    PDF »
Genome-wide search for nevus density shows linkage to two melanoma loci on chromosome 9 and identifies a new QTL on 5q31 in an adult twin cohort.
M. Falchi, T. D. Spector, U. Perks, B. S. Kato, and V. Bataille (2006)
Hum. Mol. Genet. 15, 2975-2979
   Abstract »    Full Text »    PDF »
Notch1 Signaling Promotes Primary Melanoma Progression by Activating Mitogen-Activated Protein Kinase/Phosphatidylinositol 3-Kinase-Akt Pathways and Up-regulating N-Cadherin Expression..
Z.-J. Liu, M. Xiao, K. Balint, K. S.M. Smalley, P. Brafford, R. Qiu, C. C. Pinnix, X. Li, and M. Herlyn (2006)
Cancer Res. 66, 4182-4190
   Abstract »    Full Text »    PDF »
Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
K Laud, C Marian, M F Avril, M Barrois, A Chompret, A M Goldstein, M A Tucker, P A Clark, G Peters, V Chaudru, et al. (2006)
J. Med. Genet. 43, 39-47
   Abstract »    Full Text »    PDF »
Lifetime Risk of Melanoma in CDKN2A Mutation Carriers in a Population-Based Sample.
C. B. Begg, I. Orlow, A. J. Hummer, B. K. Armstrong, A. Kricker, L. D. Marrett, R. C. Millikan, S. B. Gruber, H. Anton-Culver, R. Zanetti, et al. (2005)
J Natl Cancer Inst 97, 1507-1515
   Abstract »    Full Text »    PDF »
Population-Based Analysis of Prognostic Factors and Survival in Familial Melanoma.
S. R. Florell, K. M. Boucher, G. Garibotti, J. Astle, R. Kerber, G. Mineau, C. Wiggins, R. D. Noyes, A. Tsodikov, L. A. Cannon-Albright, et al. (2005)
J. Clin. Oncol. 23, 7168-7177
   Abstract »    Full Text »    PDF »
Mapping of a Novel Ocular and Cutaneous Malignant Melanoma Susceptibility Locus to Chromosome 9q21.32.
G. Jonsson, P.-O. Bendahl, T. Sandberg, A. Kurbasic, J. Staaf, L. Sunde, D. G. Cruger, C. Ingvar, H. Olsson, and A. Borg (2005)
J Natl Cancer Inst 97, 1377-1382
   Abstract »    Full Text »    PDF »
Hereditary Cancer Predisposition Syndromes.
J. E. Garber and K. Offit (2005)
J. Clin. Oncol. 23, 276-292
   Abstract »    Full Text »    PDF »
Absence of BRAF and NRAS Mutations in Uveal Melanoma.
F. Cruz III, B. P. Rubin, D. Wilson, A. Town, A. Schroeder, A. Haley, T. Bainbridge, M. C. Heinrich, and C. L. Corless (2003)
Cancer Res. 63, 5761-5766
   Abstract »    Full Text »    PDF »
Contribution of Germline Mutations in BRCA2, P16INK4A, P14ARF and P15 to Uveal Melanoma.
N. Hearle, B. E. Damato, J. Humphreys, J. Wixey, H. Green, J. Stone, D. F. Easton, and R. S. Houlston (2003)
Invest. Ophthalmol. Vis. Sci. 44, 458-462
   Abstract »    Full Text »    PDF »
Selective down-regulation of tyrosinase family gene TYRP1 by inhibition of the activity of melanocyte transcription factor, MITF.
D. Fang, Y. Tsuji, and V. Setaluri (2002)
Nucleic Acids Res. 30, 3096-3106
   Abstract »    Full Text »    PDF »
Perspective: Prostate Cancer Susceptibility Genes.
J. Simard, M. Dumont, P. Soucy, and F. Labrie (2002)
Endocrinology 143, 2029-2040
   Full Text »    PDF »
Molecular Aspects of Melanocytic Dysplastic Nevi.
M. R. A.-E. Hussein and G. S. Wood (2002)
J. Mol. Diagn. 4, 71-80
   Abstract »    Full Text »    PDF »
CDKN2A Mutation and Deletion Status in Thin and Thick Primary Melanoma.
A. R. Cachia, J. O. Indsto, K. M. McLaren, G. J. Mann, and M. J. Arends (2000)
Clin. Cancer Res. 6, 3511-3515
   Abstract »    Full Text »
High Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation-Positive Melanoma Families.
A. Borg, T. Sandberg, K. Nilsson, O. Johannsson, M. Klinker, A. Masback, J. Westerdahl, H. Olsson, and C. Ingvar (2000)
J Natl Cancer Inst 92, 1260-1266
   Abstract »    Full Text »    PDF »
A Locus Linked to p16 Modifies Melanoma Risk in Dutch Familial Atypical Multiple Mole Melanoma (FAMMM) Syndrome Families.
P. A. van der Velden, L. A. Sandkuijl, W. Bergman, E. T.M. Hille, R. R. Frants, and N. A. Gruis (1999)
Genome Res. 9, 575-580
   Abstract »    Full Text »    PDF »
CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
A. Ruiz, S. Puig, J. Malvehy, C. Lázaro, M. Lynch, A. M Gimenez-Arnau, L. Puig, J. Sánchez-Conejo, X. Estivill, and T. Castel (1999)
J. Med. Genet. 36, 490-493
   Abstract »    Full Text »
Functional Evidence of Novel Tumor Suppressor Genes for Cutaneous Malignant Melanoma.
C. N. Parris, J. D. Harris, D. K. Griffin, A. P. Cuthbert, A. J. R. Silver, and R. F. Newbold (1999)
Cancer Res. 59, 516-520
   Abstract »    Full Text »    PDF »
Malignant Melanoma in Children: A Review.
R. Ruiz-Maldonado and Ma. de la Luz Orozco-Covarrubias (1997)
Arch Dermatol 133, 363-371
   Abstract »    PDF »
Coexisting Malignancies in Patients With Malignant Melanoma.
K. F. Helm and S. Bittenbender (1996)
Arch Dermatol 132, 471-472
   Abstract »    PDF »
Familial Uveal Melanoma: Clinical Observations on 56 Patients.
A. D. Singh, C. L. Shields, P. De Potter, J. A. Shields, B. Trock, J. Cater, and D. Pastore (1996)
Arch Ophthalmol 114, 392-399
   Abstract »    PDF »
Familial Uveal Melanoma: Absence of Constitutional Cytogenetic Abnormalities in 14 Cases.
A. D. Singh, L. A. Donoso, L. Jackson, C. L. Shields, P. De Potter, and J. A. Shields (1996)
Arch Ophthalmol 114, 502-503
   Abstract »    PDF »
Recent Advances: Dermatology.
M. H Lowitt and N. R. Lowitt (1995)
BMJ 311, 1615-1617
   Full Text »
Increased Risk of Pancreatic Cancer in Melanoma-Prone Kindreds with p16INK4 Mutations.
A. M. Goldstein, M. C. Fraser, J. P. Struewing, C. J. Hussussian, K. Ranade, D. P. Zametkin, L. S. Fontaine, S. M. Organic, N. C. Dracopoli, W. H. Clark, et al. (1995)
N. Engl. J. Med. 333, 970-975
   Abstract »    Full Text »    PDF »
Comparison Between Familial and Nonfamilial Melanoma in France.
F. Grange, A. Chompret, M. Guilloud-Bataille, J.-C. Guillaume, A. Margulis, M. Prade, F. Demenais, and M.-F. Avril (1995)
Arch Dermatol 131, 1154-1159
   Abstract »    PDF »
Inhibitors of mammalian G1 cyclin-dependent kinases..
C J Sherr and J M Roberts (1995)
Genes & Dev. 9, 1149-1163
   PDF »
Rates of p16 (MTS1) mutations in primary tumors with 9p loss.
P Cairns, L Mao, A Merlo, D. Lee, D Schwab, Y Eby, K Tokino, P van der Riet, J. Blaugrund, and D Sidransky (1994)
Science 265, 415-417
   PDF »
New tumor suppressor may rival p53.
J Marx (1994)
Science 264, 344-345
   PDF »
Role of a Cell Cycle Regulator in Hereditary and Sporadic Cancer.
A. Kamb (1994)
Cold Spring Harb Symp Quant Biol 59, 39-47
   Abstract »    PDF »
The Morbid Cutaneous Anatomy of the Human Genome.
E. H. Epstein Jr (1993)
Arch Dermatol 129, 1417-1423
   Abstract »    PDF »
From the Clinic to the Research Laboratory: The Role of the Clinician in Molecular Genetic Studies.
S. E. Palmer and K. Stephens (1993)
Arch Dermatol 129, 1424-1429
   Abstract »    PDF »
Chromosome Location for Melanoma Risk.
(1993)
Journal Watch Dermatology 1993, 4
   Full Text »
Genetic models for studying cancer susceptibility.
S. Friend (1993)
Science 259, 774-775
   PDF »
Closing in on melanoma susceptibility gene(s).
J Travis (1992)
Science 258, 1080-1081
   PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)